



Vaccine Development and Regulations: Legal and Ethical Considerations

Nwakoby, I. P.^{1*}, Iheukwumere, I. H.^{2*}, Iheukwumere, C. M.³, Nwakoby, N. E.²,
 Idigo, M. A.⁴ and Ike, V. E.⁵

¹Department of Private and Public Law, Faculty of Law, Chukwuemeka Odumegwu Ojukwu University, Anambra State, Nigeria.

²Department of Microbiology, Faculty of Natural Sciences, Chukwuemeka Odumegwu Ojukwu University, Anambra State, Nigeria.

³Department of Applied Microbiology & Brewing, Faculty of Biosciences, Nnamdi Azikiwe University, Awka, Anambra State, Nigeria.

⁴Department of Biological Sciences, Faculty of Natural Science, Chukwuemeka Odumegwu Ojukwu University, Anambra State, Nigeria.

⁵Department of Microbiology, University of Agriculture and Environmental Sciences, Umuagwo, Imo State, Nigeria.

*Corresponding author e-mail address: ip.nwakoby@coou.edu.ng/ ik.iheukwumere@coou.edu.ng

Abstract	Article History
<p>Of the many public health interventions, vaccination stands as one of the most transformative, responsible for eradicating smallpox, curbing polio, and drastically reducing the global burden of infectious diseases. The journey from laboratory concept to licensed product, however, is a complex, costly, and highly regulated endeavor. This comprehensive review explores the multifaceted landscape of vaccine development through intersecting legal and ethical lenses. It delineates the standard multi-stage pathway for vaccine approval, from preclinical research through post-marketing surveillance, and examines the pivotal role of major regulatory agencies like the FDA and EMA in safeguarding efficacy and safety. The analysis is grounded in core ethical principles governing human subject research, including social value, informed consent, and a favorable risk-benefit ratio. Furthermore, the review investigates key legal structures, including vaccine injury compensation programs and the legal authority for mandates, while analyzing persistent tensions between intellectual property rights and equitable global access. Special ethical challenges, such as human infection studies and research in low-resource settings, are also addressed. The COVID-19 pandemic serves as a central case study, stress-testing these established frameworks. The unprecedented acceleration of development, reliance on Emergency Use Authorizations, and the stark emergence of vaccine nationalism highlighted both the remarkable agility of regulatory systems and profound vulnerabilities in global equity and public trust. The conclusion emphasizes that while the system successfully balanced urgency with prudence during the crisis, future preparedness requires strengthened regulatory harmony, robust manufacturing capacity, and more effective strategies to combat misinformation and uphold ethical commitments to global justice.</p> <p>Keywords: <i>Vaccine development, regulatory frameworks, bioethics, global health equity, COVID-19 pandemic</i></p>	<p>Received: 28 Sept 2025 Accepted: 18 Oct 2025 Published: 26 Oct 2025</p>
<p>How to cite this paper: Nwakoby, I. P., Iheukwumere, I. H., Iheukwumere, C. M., Nwakoby, N. E., Idigo, M. A., & Ike, V. E. (2025). <i>Vaccine development and regulations: Legal and ethical considerations</i>. <i>IPS Journal of Public Health, 5(4)</i>, 456–460. https://doi.org/10.54117/02eabv98</p>	<div data-bbox="1171 936 1423 1137" data-label="Image"> </div> <p data-bbox="1187 1137 1407 1169">Scan QR code to view*</p> <p data-bbox="1187 1196 1391 1227">License: CC BY 4.0*</p> <div data-bbox="1165 1227 1433 1281" data-label="Image"> </div> <p data-bbox="1203 1281 1394 1303">Open Access article.</p>

1. Introduction

Vaccines represent one of the most profound achievements in medical science and public health. Since Edward Jenner's pioneering work with smallpox in the 18th century, vaccination programs have led to the eradication of smallpox, the near-elimination of polio, and the significant reduction of morbidity and mortality from countless infectious diseases like measles, diphtheria, and tetanus (Plotkin, 2014; Iheukwumere *et al.*, 2025a; Iheukwumere *et al.*, 2025b). The benefits extend beyond individual protection, conferring herd immunity that safeguards vulnerable populations who cannot be vaccinated due to age or medical conditions.

However, the process of bringing a vaccine from a laboratory concept to a licensed product administered to billions is immensely complex, costly, and time-consuming. It is a journey fraught with scientific uncertainty, immense financial risk, and profound ethical and legal dilemmas. This process is not undertaken in a vacuum; it is rigidly governed by a sophisticated global ecosystem of regulations designed to ensure safety and efficacy, and guided by enduring ethical principles designed to protect human rights and dignity (Lurie *et al.*, 2020).

The development of COVID-19 vaccines, achieved at an unprecedented pace, served as a global case study, placing the

♦ This work is published open access under the [Creative Commons Attribution License 4.0](https://creativecommons.org/licenses/by/4.0/), which permits free reuse, remix, redistribution and transformation provided due credit is given.

intricate systems of vaccine regulation and ethics under a powerful spotlight (EMA, 2021). It highlighted both the remarkable agility of these systems under pressure and the persistent challenges of equitable access, public trust, and navigating uncharted ethical territory (Lurie *et al.*, 2020).

This comprehensive review will explore the multifaceted landscape of vaccine development and regulation through legal and ethical lenses. It will delineate the standard pathway for vaccine approval, examine the roles of major regulatory agencies, delve into the core ethical principles guiding human subject research, analyze key legal structures governing liability and mandates, and discuss special ethical challenges. The COVID-19 pandemic will be used as a central case study to illustrate the dynamic application—and strain—of these frameworks in a real-world crisis.

2. The Vaccine Development Lifecycle: A Primer

The traditional vaccine development pathway is a sequential, multi-stage process that typically spans 10-15 years. Each stage acts as a gating mechanism to ensure only the safest and most promising candidates advance.

2.1. Preclinical Stage

This exploratory stage involves basic laboratory research and animal studies. Scientists identify potential antigens (virus-like particles, weakened viruses, viral subunits, etc.) that could trigger a protective immune response. Animal models are used to assess the vaccine candidate's safety (e.g., toxicity) and immunogenicity (its ability to provoke an immune response) (Iheukwumere *et al.*, 2025c; Iheukwumere *et al.*, 2025d). Successful preclinical data is required to file an Investigational New Drug (IND) application with regulators like the FDA to seek permission to begin human trials (FDA, 2021; Iheukwumere *et al.*, 2025e; Iheukwumere *et al.*, 2025f).

2.2. Clinical Development (Phases I-III)

Phase I trials focus primarily on safety and dosage. They involve a small number (20-100) of healthy volunteers and aim to identify common short-term side effects and how the vaccine is metabolized.

Phase II trials expand to several hundred participants and are randomized and controlled, often using a placebo. They continue to assess safety, immunogenicity, and determine the proposed dosage schedule and method of delivery (e.g., injection).

Phase III trials are large-scale studies involving thousands to tens of thousands of participants. They are designed to confirm efficacy—does the vaccine prevent the disease?—and to gather more comprehensive data on safety across a broader population. This phase is critical for identifying rarer adverse events that may not be apparent in smaller groups (Lurie *et al.*, 2020; Iheukwumere *et al.*, 2025g; Iheukwumere *et al.*, 2025h).

2.3. Regulatory Review and Approval

Upon successful completion of Phase III, the vaccine sponsor submits a Biologics License Application (BLA) in the U.S. or a Marketing Authorization Application (MAA) in Europe. This application is a massive dossier containing all preclinical and clinical data, details on manufacturing processes and

facility quality. Teams of regulatory scientists, physicians, and statisticians meticulously review the data to determine if the vaccine is safe, effective, and that its manufacturing is consistent and controlled (Iheukwumere *et al.*, 2025i; Iheukwumere *et al.*, 2025j). An advisory committee may hold a public meeting to provide independent expert advice before the agency makes a final approval decision (EMA, 2021).

2.4. Post-Marketing Surveillance (Phase IV)

Monitoring does not stop at approval. Phase IV refers to ongoing surveillance after the vaccine is on the market. Regulators and manufacturers continue to monitor safety in the general population to detect very rare or long-term adverse events that may not have been observable in clinical trials. Systems like the Vaccine Adverse Event Reporting System (VAERS) in the U.S. and EudraVigilance in Europe are crucial for this pharmacovigilance (Chen *et al.*, 2019; Iheukwumere *et al.*, 2025k; Iheukwumere *et al.*, 2025l).

3. The Regulatory Framework: Guardians of Safety and Efficacy

National Regulatory Authorities (NRAs) are the gatekeepers of the pharmaceutical market, tasked with protecting public health by ensuring that medicines and vaccines meet stringent standards.

3.1. The United States Food and Drug Administration (FDA)

The FDA's Center for Biologics Evaluation and Research (CBER) is responsible for regulating vaccines in the U.S. Its authority is derived from the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act. The FDA oversees the entire lifecycle, from reviewing INDs and BLAs to inspecting manufacturing facilities. Its approval is considered a global gold standard (FDA, 2021; Ekechukwu *et al.*, 2025a; Ekechukwu *et al.*, 2025b; Ekechukwu *et al.*, 2025c).

3.2. The European Medicines Agency (EMA)

The EMA operates a centralized authorization procedure for human medicines, including vaccines, for all member states of the European Union. The Committee for Medicinal Products for Human Use (CHMP) conducts the scientific assessment. While the EMA grants the marketing authorization, pricing and reimbursement decisions remain with individual member states (EMA, 2021; Dim *et al.*, 2025a; Dim *et al.*, 2025b).

3.3. Other Major Regulatory Bodies

World Health Organization (WHO): The WHO does not regulate products itself but plays a critical role in prequalifying vaccines for purchase by UN agencies (e.g., UNICEF). It also supports the strengthening of NRAs in low-resource countries. *Pharmaceuticals and Medical Devices Agency (PMDA) - Japan*: Japan's regulatory body, known for its rigorous review process.

Health Canada (HC): Canada's federal department responsible for national health policy and the regulation of vaccines.

3.4. The Role of Emergency Use Authorization (EUA)

An EUA is a legal mechanism that allows the use of unapproved medical products during a declared public health emergency. The standard for an EUA is lower than for full approval; the FDA must determine that the known and

potential benefits of the vaccine outweigh the known and potential risks, based on the totality of scientific evidence available (Dim *et al.*, 2025c; Ike *et al.*, 2025a; Ike *et al.*, 2025b). This mechanism was used extensively for COVID-19 vaccines to expedite access while full BLA reviews were ongoing. It is not a substitute for approval and requires ongoing data collection (Battacharya, 2020; Ike *et al.*, 2025c; Ike *et al.*, 2025d; Ike *et al.*, 2025e).

4. Core Ethical Principles in Vaccine Development and Trials

The ethical conduct of clinical research is codified in international guidelines, most notably the Belmont Report and the Declaration of Helsinki. Their principles are the bedrock of vaccine trials.

4.1. Social Value and Scientific Validity

Research must be designed to answer useful questions that contribute to scientific understanding and public health. A poorly designed trial that cannot yield interpretable results is unethical as it exposes participants to risk for no benefit (Emanuel *et al.*, 2000; Ugwu *et al.*, 2025a; Ugwu *et al.*, 2025b).

4.2. Favourable Risk-Benefit Ratio

Risks to participants must be minimized and must be justified by the anticipated benefits to the participants and the societal value of the knowledge gained. For vaccines, this involves careful consideration of the risk of the experimental vaccine versus the risk of the disease it is meant to prevent (Amadi *et al.*, 2017; Nwike *et al.*, 2017; Ekesiobi *et al.*, 2025).

4.3. Independent Review and Informed Consent

All research protocols must be reviewed and approved by an independent Institutional Review Board (IRB) or Ethics Committee (EC). Furthermore, the principle of informed consent is paramount. Participants must voluntarily agree to participate after understanding the purpose, procedures, risks, benefits, and alternatives to the research. The consent process must be free of coercion and undue influence (National Commission for the Protection of Human Subjects, 1979).

4.4. Respect for Potential and Enrolled Subjects

This principle encompasses protecting the privacy of participants, allowing them to withdraw from a study at any time without penalty, and monitoring their welfare throughout the trial.

5. Legal Considerations: Liability, Mandates, and Equity

5.1. Vaccine Injury Compensation Programs

Vaccines, like all medicines, carry a risk of adverse events. To ensure a stable vaccine supply, the U.S. established the National Vaccine Injury Compensation Program (VICP) in 1988. It is a no-fault alternative to the traditional tort system. Individuals claiming injury from a covered vaccine must file a petition with the U.S. Court of Federal Claims. The program is funded by an excise tax on each dose of vaccine. This system protects manufacturers from debilitating lawsuits while providing a streamlined process for compensating legitimate injuries (Evans, 2006).

5.2. The Legal Authority for Vaccination Mandates

The authority to mandate vaccines is well-established in law, rooted in the state's police power to protect public health. The seminal U.S. Supreme Court case *Jacobson v. Massachusetts (1905)* upheld the authority of states to enforce compulsory vaccination laws. Mandates are typically implemented for school entry, certain professions (e.g., healthcare workers), and military service. These mandates are subject to constitutional scrutiny but are generally upheld if they are rationally related to a legitimate state interest and provide medical exemptions (Mariner *et al.*, 2005).

5.3. Intellectual Property and Access to Medicines (TRIPS)

Intellectual Property (IP) rights, particularly patents, grant manufacturers temporary monopolies to recoup R and D investments. However, this can create a tension with global equity, as high prices can put vaccines out of reach for low-income countries. The World Trade Organization's Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) sets minimum standards for IP protection but also includes flexibilities, such as compulsory licensing, which allows a government to authorize the production of a patented product without the consent of the patent owner in certain circumstances. The debate over a COVID-19 "TRIPS waiver" highlighted this ongoing tension between innovation incentives and equitable access (Hoen *et al.*, 2021).

6. Special Ethical Challenges

6.1. Challenge Trials (Human Infection Studies)

In a challenge trial, volunteers are intentionally infected with a pathogen after receiving either an experimental vaccine or a placebo. This can dramatically accelerate efficacy testing. However, it raises profound ethical questions, especially for diseases with no reliable rescue treatment (e.g., early COVID-19). Proponents argue it can save countless lives by speeding up development; opponents stress the unacceptable risk of harming healthy volunteers (Deming *et al.*, 2020).

6.2. Pediatric and Maternal Vaccination

Children are a vulnerable population and cannot provide legal consent (assent is sought). Therefore, ethical standards for pediatric trials are even stricter. Vaccinating pregnant women presents a unique challenge of protecting two patients—the mother and the fetus—and historically, they have been excluded from initial clinical trials, often leaving them without evidence-based guidance (Krubiner *et al.*, 2021).

6.3. Research in Low- and Middle-Income Countries (LMICs)

When research is conducted in LMICs by sponsors from high-income countries, concerns about ethical imperialism and exploitation arise. The research must be responsive to the health needs of the host community, and any product developed must be made reasonably available to that community post-trial. Ensuring genuine informed consent in contexts with low literacy and different cultural understandings of medicine is also a critical challenge (London and Kimmelman, 2020).

6.4. Vaccine Hesitancy and Misinformation

Vaccine hesitancy, defined as a delay in acceptance or refusal of vaccines despite availability, is a complex threat to public

health. It is fueled by a mix of factors, including complacency, inconvenience, lack of confidence, and, crucially, misinformation spread via media and social networks. Ethically and legally, addressing hesitancy requires transparent communication, building trust in institutions, and combating falsehoods without dismissing legitimate public concerns (Dubé *et al.*, 2013).

7. Case Study: The Covid-19 Pandemic – A Stress Test for Systems

The COVID-19 pandemic was a paradigm-shifting event that tested every aspect of the vaccine ecosystem.

7.1. Accelerated Development: Operation Warp Speed and Beyond

The development of multiple safe and effective vaccines within a year was a historic feat. This was achieved not by skipping steps, but through unprecedented collaboration and resource allocation. Key accelerants included: massive public funding (e.g., Operation Warp Speed in the U.S.), conducting trial phases in parallel instead of sequentially, rolling reviews by regulators (assessing data as it came in), and scaling up manufacturing at financial risk before approval was granted (Lurie *et al.*, 2020).

7.2. EUA as a Global Tool

The EUA mechanism became the primary initial pathway for authorizing COVID-19 vaccines globally. This allowed for rapid deployment while companies continued to collect data for full approval. It demonstrated the flexibility of regulatory systems but also created public confusion about the difference between an EUA and full licensure, contributing to hesitancy.

7.3. Vaccine Nationalism and Global Equity (COVAX)

The pandemic starkly revealed global inequities. High-income countries secured advance purchase agreements for billions of doses, often hoarding supply, while LMICs were left behind. The WHO-led COVAX facility aimed to ensure equitable global access but was hampered by insufficient funding, export bans, and supply chain issues. This "vaccine apartheid" raised serious ethical questions about justice and solidarity in global health (Usher, 2021).

8. Conclusion

The development and regulation of vaccines sit at the complex intersection of science, commerce, public health, law, and ethics. The system is fundamentally designed to be cautious, prioritizing safety and efficacy above speed. The COVID-19 pandemic proved that this system could be accelerated to a remarkable degree without sacrificing its core principles, thanks to global scientific collaboration, regulatory agility, and immense public investment.

However, the pandemic also exposed critical vulnerabilities: the fragility of global equity, the pervasive threat of misinformation, and the ethical dilemmas inherent in crisis research. Moving forward, the lessons are clear. The global community must strengthen regulatory harmonization, build robust manufacturing capacity in underserved regions, establish clearer ethical frameworks for research during emergencies, and develop more effective strategies for transparent communication and combating misinformation.

The legal and ethical frameworks governing vaccines are not static rulebooks; they are living systems that must evolve alongside scientific advancement and societal values. The ultimate goal remains constant: to deliver safe, effective, and equitable vaccines to protect global public health, while steadfastly upholding the rights and dignity of every individual.

References

- Amadi, R.E., Iheukwumere, I.H. and Unaeze, B.C. (2017). Effects Of Crude Alkaloid Extracted From *Ocimum Gratissimum* On The Activity Of Ciprofloxacin Against *Salmonella* Enterica Serovar Typhi. *Advances in Life Science and Technology* 58.
- Bhattacharya, D. (2020). The Law of Emergency Use Authorizations and the COVID-19 Pandemic. *Food and Drug Law Journal* 75(3): 321 – 333.
- Chen, R. T. (2019). The Vaccine Safety Datalink: Successes and Challenges Monitoring Vaccine Safety. *Vaccine* 37(15), 2139-2142.
- Deming, M. E. (2020). Accelerating Development of SARS-CoV-2 Vaccines — The Role for Controlled Human Infection Models. *New England Journal of Medicine* 383: 52 – 63.
- Dim, C. N., Iheukwumere, I. H., Iheukwumere, C. M., Ugwu, C. H., Ike, V. E., Ezendianefo, J. N., Egbe, P. A., Oragwu, I. P., Orji, C. C., Ogbonnaya, O. C., Onwuasoanya, U. F., Okereke, F. O., Oduenyi, P. M., & Ochibulu, S. C. (2025a). Multiple Antibiotic Resistance Bacterial Strains in Frozen Meat Sold at Abagana, Anambra State: A Public Health Concern. *IPS Journal of Applied Microbiology and Biotechnology*, 4(3), 181–186. <https://doi.org/10.54117/ijamb.v4i3.75>
- Dim, C. N., Iheukwumere, I. H., Iheukwumere, C. M., Ugwu, C. H., Ike, V. E., Ezendianefo, J. N., Egbe, P. A., Oragwu, I. P., Orji, C. C., Ogbonnaya, O. C., Onwuasoanya, U. F., Okereke, F. O., Oduenyi, P. M., & Ochibulu, S. C. (2025b). The Burden of Antibiotic Resistance: Evaluating the Impact of Multiple Antibiotic-Resistant Enteric Bacteria in Academic Environments. *IPS Interdisciplinary Journal of Biological Sciences*, 4(4), 144–149. <https://doi.org/10.54117/ijibs.v4i4.78>
- Dim, C. N., Iheukwumere, I. H., Iheukwumere, C. M., Ugwu, C. H., Ike, V. E., Ezendianefo, J. N., Egbe, P. A., Oragwu, I. P., Orji, C. C., Ogbonnaya, O. C., Onwuasoanya, U. F., Okereke, F. O., Oduenyi, P. M., & Ochibulu, S. C. (2025c). Antimicrobial resistance in aquaculture: evaluating *Pseudomonas aeruginosa* from fish ponds. *IPS Intelligentia Multidisciplinary Journal*, 4(1), 32–36. <https://doi.org/10.54117/iimj.v4i1.10>
- Dubé, E. (2013). Vaccine hesitancy: an overview. *Human Vaccines and Immunotherapeutics* 9(8): 1763–1773.
- Ekechukwu, C. C., Umeh, S. O., Iheukwumere, I. H., & Iheukwumere, C. M. (2025a). Bacterial Loads of Smoked Fish and Chicken: Role of pH and Moisture Content. *IPS Applied Journal of Nutrition, Food and Metabolism Science*, 3(1), 44–49. <https://doi.org/10.54117/iajnfms.v3i1.102>
- Ekechukwu, C. C., Umeh, S. O., Iheukwumere, I. H., & Iheukwumere, C. M. (2025b). Biological Inhibition of Pathogenic Bacteria Isolated from Smoked Fish and Chicken: An In Vitro Study. *IPS Interdisciplinary Journal of Biological Sciences*, 4(2), 85–92. <https://doi.org/10.54117/ijbs.v4i2.50>
- Ekechukwu, C. C., Umeh, S. O., Iheukwumere, I. H., & Iheukwumere, C. M. (2025c). Prophylactic Potential of the Most Potent Synergistic Biological Agent against Bacterial Infections from Smoked Fish and Chicken. *IPS Journal of Applied Microbiology and Biotechnology*, 4(2), 153–160. <https://doi.org/10.54117/ijamb.v4i2.57>
- Ekesiobi, A. O., Iheukwumere, C. M., Iheukwumere, I. H., Ejike, C. E., Ekechukwu, C. C., Ike, V. E., Okereke, F. O., & Ochibulu, S. C. (2025). Hyping the Inhibitory Activity of *Xylopiia aethiopia* against *Vibrio cholerae* using Azithromycin. *IPS Journal of Basic and Clinical Medicine*, 2(3), 93–98. <https://doi.org/10.54117/ijbcm.v2i3.16>
- Emanuel, E. J., Wendler, D. and Grady, C. (2000). What makes clinical research ethical? *JAMA* 283(20): 2701-2711.
- European Medicines Agency (EMA). (2021). Guideline on clinical evaluation of new vaccines.
- Evans, G. (2006). Vaccine Injury Compensation Programs: An Overview. Congressional Research Service Report for Congress.
- Food and Drug Administration (FDA). (2021). Development and Licensure of Vaccines to Prevent COVID-19: Guidance for Industry. U.S. Department of Health and Human Services.
- Hoen, E. F. M. (2021). A Patent Waiver on COVID-19 Vaccines: Beyond the Rhetoric. *The Lancet* 397(10288): 1894-1895.

- Iheukwumere, I. H., Ajeh, J. C., Iheukwumere, C. M., Ike, V. E., Obianom, A. O., Ihenatuoha, U. A., Igboanugo, E. U., Onwuasoanya, U. F., Okereke, F. O., Nnadozie, C. H., Agbaugo, C. F., Nwike, M. I., Nwakoby, N. E., & Ihechukwu, C. C. (2025l). Exploring the Phytochemical and Antimicrobial Properties of Fruit Vinegar: A Study on Phoenix Dactylifera and Malus Sylvestris. *IPS Journal of Applied Microbiology and Biotechnology*, 4(1), 115–122. <https://doi.org/10.54117/ijamb.v4i1.48>
- Iheukwumere, I. H., Iheukwumere, C. M., Idigo, M. A., & Ezekwueche, S. N. (2025a). *Lactobacillus* fermentation of chicken feather: Impact on structural development and immune system of albino Wistar rats. *IPS Applied Journal of Nutrition, Food and Metabolism Science*, 3(2), 75–83. <https://doi.org/10.54117/qabcj082>
- Iheukwumere, I. H., Iheukwumere, C. M., Idigo, M. A., & Ezekwueche, S. N. (2025b). Evaluation of *Lactobacillus* fermented chicken feather meal on blood lipoproteins and lymphocyte count in rats. *IPS Journal of Nutrition and Food Science*, 4(4), 569–577. <https://doi.org/10.54117/012d8612>
- Iheukwumere, I. H., Iheukwumere, C. M., Idigo, M. A., & Ezekwueche, S. N. (2025c). Exploring the impact of *Lactobacillus*-fermented chicken feather on organ weights and functions in albino Wistar rats. *IPS Journal of Toxicology*, 3(3), 68–75. <https://doi.org/10.54117/zc1h5865>
- Iheukwumere, I. H., Iheukwumere, C. M., Idigo, M. A., & Ezekwueche, S. N. (2025d). Corollary of *Lactobacillus* Fermented Chicken Feather on Organ-Weight and Leukocyte Indices of Broiler Chicks. *IPS Intelligensia Multidisciplinary Journal*, 4(1): 46-53. <https://doi.org/10.54117/iimj.v4i1.12>
- Iheukwumere, I. H., Iheukwumere, C. M., Idigo, M. A., & Ezekwueche, S. N. (2025e). Fermented Chicken Feather Meal as a Potential Feed Supplement: Effects on Body Weight and Immune Function. *IPS Intelligensia Multidisciplinary Journal*, 4(1), 37–45. <https://doi.org/10.54117/iimj.v4i1.11>
- Iheukwumere, I. H., Iheukwumere, C. M., Idigo, M. A., & Ezekwueche, S. N. (2025f). Corollary of *Lactobacillus* Fermented Chicken Feather on Growth Performance of Rats. *IPS Journal of Biotechnology and Applied Biochemistry*, 1(2), 57–65. <https://doi.org/10.54117/ijbab.v1i2.85>
- Iheukwumere, I. H., Iheukwumere, C. M., Idigo, M. A., & Ezekwueche, S. N. (2025g). Corollary of *Lactobacillus* Fermented Chicken Feather on Growth Performance of Rats. *IPS Journal of Biotechnology and Applied Biochemistry*, 1(2), 57–65. <https://doi.org/10.54117/ijbab.v1i2.85>
- Iheukwumere, I. H., Iheukwumere, C. M., Idigo, M. A., & Ezekwueche, S. N. (2025h). Fermented Chicken Feather as a Sustainable Feed Ingredient: Effects on Broiler Chick Health and Growth. *IPS Interdisciplinary Journal of Biological Sciences*, 4(4), 157–165. <https://doi.org/10.54117/ijbs.v4i4.84>
- Iheukwumere, I. H., Iheukwumere, C. M., Idigo, M. A., & Ezekwueche, S. N. (2025i). Assessment of Fermented Corn Mixed with Fish Meal as a Chicken Additive for Healthy Broiler Chicks. *Journal of Agriculture, Food Technology and Sustainability*, 2(1), 60–68. <https://doi.org/10.54117/jafts.v2i1.82>
- Iheukwumere, I. H., Iheukwumere, C. M., Idigo, M. A., & Ezekwueche, S. N. (2025j). Evaluation of Fermented Corn Residue as a Growth Promoter in Broiler Chicken Diets. *Journal of Agriculture, Food Technology and Sustainability*, 2(1), 69–77. <https://doi.org/10.54117/jafts.v2i1.83>
- Iheukwumere, I. H., Iheukwumere, C. M., Obianom, A. O., Nnadozie, C. H., Okereke, F. O., Onwuasoanya, U. F., ... Destiny, E. C. (2025k). Cross-Sectional Study of Major Strains of *Salmonella enterica* Subspecies *Enterica* Serovar Typhi among Borehole Used in Uli Community. *IPS Journal of Public Health*, 5(2), 205–210. <https://doi.org/10.54117/ijph.v5i2.40>
- Ike, V. E., Iheukwumere, I. H., Iheukwumere, C. M., Dim, C. N., Ezendianefo, J. N., Egbe, P. A., Oragwu, I. P., Orji, C. C., Ogbonnaya, O. C., Onwuasoanya, U. F., Okereke, F. O., & Ochibulu, S. C. (2025a). Prevalence of *Bacillus cereus* in Powdered Soybean Sold in Uli Community, Anambra State: A Cross-Sectional Study. *IPS Journal of Basic and Clinical Medicine*, 2(3), 108–114. <https://doi.org/10.54117/ijbcm.v2i3.18>
- Ike, V. E., Iheukwumere, I. H., Iheukwumere, C. M., Dim, C. N., Ezendianefo, J. N., Egbe, P. A., Oragwu, I. P., Orji, C. C., Ogbonnaya, O. C., Onwuasoanya, U. F., Okereke, F. O., & Ochibulu, S. C. (2025b). *Bacillus cereus* in Uli's cornflour: A prevalence study. *IPS Journal of Nutrition and Food Science*, 4(3), 544–548. <https://doi.org/10.54117/8bte840>
- Ike, V. E., Iheukwumere, I. H., Iheukwumere, C. M., Dim, C. N., Ezendianefo, J. N., Egbe, P. A., Oragwu, I. P., Orji, C. C., Ogbonnaya, O. C., Onwuasoanya, U. F., Okereke, F. O., & Ochibulu, S. C. (2025c). Pathogenic Profile Analysis: In Vitro Screening of Enteric Bacteria from University Dusters. *IPS Journal of Applied Microbiology and Biotechnology*, 4(3), 187–191. <https://doi.org/10.54117/ijamb.v4i3.76>
- Ike, V. E., Iheukwumere, I. H., Iheukwumere, C. M., Dim, C. N., Ezendianefo, J. N., Egbe, P. A., Oragwu, I. P., Orji, C. C., Ogbonnaya, O. C., Onwuasoanya, U. F., Okereke, F. O., & Ochibulu, S. C. (2025d). Frozen Fish Pathogens: Antimicrobial Resistance and Public Health Implications. *IPS Interdisciplinary Journal of Biological Sciences*, 4(4), 138–143. <https://doi.org/10.54117/ijbs.v4i4.77>
- Ike, V. E., Iheukwumere, I. H., Iheukwumere, C. M., Dim, C. N., Ezendianefo, J. N., Egbe, P. A., Oragwu, I. P., Orji, C. C., Ogbonnaya, O. C., Onwuasoanya, U. F., Okereke, F. O., & Ochibulu, S. C. (2025e). Stream water quality assessment: Antibiotic resistance of Lac-positive enteric bacterial isolates. *Journal of Pollution Monitoring, Evaluation Studies and Control*, 4(2), 120–125. <https://doi.org/10.54117/jpmesc.v4i2.21.2025>
- Jacobson v. Massachusetts, 197 U.S. 11 (1905).
- Krubiner, C. B. (2021). Pregnant People and the COVID-19 Vaccine: A Guidelines Landscape Analysis. Johns Hopkins Bloomberg School of Public Health.
- London, A. J. and Kimmelman, J. (2020). Against pandemic research exceptionalism. *Science* 368(6490): 476-477.
- Lurie, N. (2020). Developing Covid-19 Vaccines at Pandemic Speed New England. *Journal of Medicine* 382: 1969 – 1973
- Mariner, W. K., Annas, G. J. and Glantz, L. H. (2005). Jacobson v Massachusetts: It's Not Your Great-Great-Grandfather's Public Health Law. *American Journal of Public Health* 95(4): 581–590.
- National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. (1979). The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. U.S. Department of Health and Human Services.
- Nwike, M.I., Iheukwumere, I.H. and Uneze, B.C. (2017). Effect of Spices, pH and Temperature on the Survival and Multiplication of *Staphylococcus aureus* in Locally Made Soya Milk Drink. *Journal of Natural Sciences Research* 7(4):1-9
- Plotkin, S. A. (2014). History of vaccination. *Proceedings of the National Academy of Sciences* 111(34): 12283-12287.
- Ugwu, C. H., Iheukwumere, I. H., Iheukwumere, C. M., Ike, V. E., Dim, C. N., Ezendianefo, J. N., Egbe, P. A., Oragwu, I. P., Orji, C. C., Ogbonnaya, O. C., Onwuasoanya, U. F., Okereke, F. O., Oduenyi, P. M., & Ochibulu, S. C. (2025a). Maternal health and antibiotic resistance: *Klebsiella pneumoniae* isolates analysis. *IPS Journal of Public Health*, 5(3), 290–295. <https://doi.org/10.54117/s3tx6v26>
- Ugwu, C. H., Iheukwumere, I. H., Iheukwumere, C. M., Ike, V. E., Dim, C. N., Ezendianefo, J. N., Egbe, P. A., Oragwu, I. P., Orji, C. C., Ogbonnaya, O. C., Onwuasoanya, U. F., Okereke, F. O., Oduenyi, P. M., & Ochibulu, S. C. (2025b). *Ocimum gratissimum* Extract's Effectiveness against *Vibrio cholerae* from Uli Streams. *IPS Journal of Phytochemistry and Medicinal Plant Research*, 1(2), 15–19. <https://doi.org/10.54117/ijpmpr.v1i2.38>
- Usher, A. D. (2021). A beautiful idea: how COVAX has fallen short. *The Lancet* 397(10292): 2322 – 2325.
- World Medical Association. (2013). WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects.

*Thank you for publishing with us.